Back to Search
Start Over
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer
- Source :
- Cancer Biology & Medicine, Vol 20, Iss 12, Pp 1047-1059 (2023)
- Publication Year :
- 2023
- Publisher :
- China Anti-Cancer Association, 2023.
-
Abstract
- Objective: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients. Methods: This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone
Details
- Language :
- English
- ISSN :
- 20953941
- Volume :
- 20
- Issue :
- 12
- Database :
- Directory of Open Access Journals
- Journal :
- Cancer Biology & Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.740ba6f7e2c940af8ffebb36db2754d7
- Document Type :
- article
- Full Text :
- https://doi.org/10.20892/j.issn.2095-3941.2023.0335